MaRS Centre, South Tower
101 College Street
MolecuLight Inc. is a privately owned, Canadian medical imaging company with applications in multiple areas from its platform technology. Its current product in wound care delivers a real-time fluorescence image-guidance solution that provide clinicians with new information about wound bacterial burden and wound size to assist clinicians in making improved diagnostic and treatment decisions. MolecuLight's product roadmap includes applications in oncology.
Founder and CSO: Ralph DaCosta
CEO: Anil Amlani
29 articles with MolecuLight
In new publication, 96% of clinicians state that treatment plans informed using the MolecuLight procedure led to improved wound healing
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of an independent consensus study of 32 leading wound care clinicians in Diagnostics1.
MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces it has signed LMT Surgical as its new Distributor in Australia and New Zealand.
MolecuLight Announces Integration of its i:X® Fluorescence Imaging Device with Net Health's Tissue Analytics API Program
Patient Wounds Documented by MolecuLight i:X Device Now Integrated with EHR Systems Through Net Health's Tissue Analytics Platform
Distributors' Extensive Support and Technical Expertise will Meet Growing Global Demand for the MolecuLight i:X® Fluorescence Wound Imaging Device
MolecuLight i:X® Platform Available to 650 Long-Term Healthcare Facilities Through Synergy HealthCare Alliance, LLC
MolecuLight Inc., the leader in fluorescence imaging for point-of-care detection of wounds containing elevated bacterial loads, announces the availability of its MolecuLight i:X® platform to 650 long-term healthcare facilities in the US through its new commercial arrangement with Synergy HealthCare Alliance, LLC.
Results Published in Study Show MolecuLight Fluorescence Point-of-Care Imaging Detected Pseudomonas Aeruginosa (PA) in Wounds with a PPV of 93%
Study Reveals the Utility of Cyan Fluorescence to Reliably Predict Pseudomonas, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods
Wound Care Plus, LLC Adopts the MolecuLight i:X® as a Standard Point-of-Care Device for its Wound Care Service Offering to the Long-Term Care and Extended Care Markets
MolecuLight i:X will Provide Essential Real-Time Information to Assist Wound Care Plus's Advanced Wound Care Consultants in Providing the Highest Quality Wound Care
Results Published from 2-Year Study of 229 Wounds Treated in an NHS Clinic Show Fluorescence Point-of-Care Imaging Improved Wound Healing Rates by 23%
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing bacteria, announced the publication of results from a 2-year retrospective study of 229 foot ulcers in Diagnostics.
Results from 350-Patient FLAAG Trial Show MolecuLight Point-of-Care Imaging Improves Detection of High Bacterial Burden in Wounds Four-fold over Standard of Care Assessment
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announced publication of results from the Fluorescence Imaging Assessment and Guidance clinical trial in Advances in Wound Care.
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces the availability of its MolecuLight i:X® platform on theEpic App Orchard Marketplace and the integration of its platform with Epic's leading EMR platform.
Latest Clinical Evidence Presented at SAWC 2020 Illustrates the Significant Utility of the MolecuLight i:X® for Visualizing Bacteria and Improving Clinical Outcomes
10 Clinical Posters and Video Presentations Highlight the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Practitioners
New Telemedicine Solution allows the MolecuLight i:X Device to be used at the Bedside for Synchronous Interpretation of the Images by Remote Wound Care Clinicians
MolecuLight Launches i:X® Sterile Surgical Sleeve for Imaging of Bacteria in Wounds in a Surgical Setting
New Disposable Sleeve allows MolecuLight i:X to Be Used in Operating Rooms (for skin grafts and skin substitutes), in Covid-19 Wards and in MRSA Isolation Wards
Leading GPO Accepts MolecuLight i:X Point-of-Care Device for Detection of Bacteria and Digital Wound Measurement for its National Membership
MolecuLight Announces CMS has Assigned an APC Reimbursement Code for its MolecuLight i:X® Procedure for Bacterial Imaging using Fluorescence
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X imaging procedure for point-of-care real-time fluorescence wound imaging for bacterial presence, location and load
MolecuLight Announces Strategic Alliance with Tissue Analytics to Integrate its MolecuLight i:X® Platform with Leading EMR / EHR Platforms
MolecuLight i:X's Fluorescence Images, Movies and Digital Measurements of Patient Wounds can now be Saved and Accessed with EMR / EHR Systems Through Tissue Analytics Platform
MolecuLight Announces Industry Partnership and Virtual Exhibit of its MolecuLight i:X® Platform at WoundCon™ 2020, the Largest Conference for Wound Care
Novel Virtual Conference Attracts 10,000 Wound Care Professionals as Alternate to Live Medical Conferences Given Travel Challenges Due to Covid-19
First Published Study to Report In Vitro Detection of Fluorescence from Bacteria in Biofilm with Point-of-care Wound Imaging Device
MolecuLight Inc., the world's leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, announces the publication of "In vitro detection of porphyrin-producing wound bacteria with real-time fluorescence imaging" in Future Microbiology.
i:X Platform's Precise Wound Measurement, along with Fluorescence Imaging, for More Accurate Detection and Ongoing Documentation of Wounds
American Medical Association Issues Category lll CPT® Codes for Real-time Fluorescence Wound Imaging
Reimbursement Pathway Established for MolecuLight's i:X Procedure in Wound Care